ABSTRACT To study the luteinizing hormone-releasing hormone (LH-RH; luliberin) (7) (8) (9) (10) (11) (12) . Because the antifertility effects of LH-RH and its analogs are parallel to their gonadotropin-releasing potency, the loss of ovarian gonadotropin receptors and inhibition of steroidogenesis could be due at least partly to endogenous luteinizing hormone (LH) release (5, 11, 13). However, direct ovarian effects of LH-RH agonists have been observed in female rats (14-17). LH-RH agonists have also been found to inhibit steroid secretion stimulated by human choriogonadotropin or follicle-stimulating hormone in rat luteal and granulosa cells (17-19 500 ,uCi (1 Ci = 3.7 X 1010 becquerels) of carrier-free Nal25I, and 600 ng of chloramine-T in 10,Ml of 0.5 M sodium phosphate (pH 7.2). The reaction was stopped by adding 1 ml of eluant buffer (10 mM Tris-HCI/0.1% bovine serum albumin/0.1% NaN3, pH 7.6 at 250C) and immediately layering onto a 1 X 55 cm column of Sephadex G-25 (fine). This procedure has been shown to separate monoiodinated and diiodinated hormones (20). Free 125I eluted as the first radioactive peak; monoiodinated [D-Ser(TBU)6]-LH-RH-EA appeared as the second radioactive peak. As of maximal effect.
and can exert luteolytic and antiovulatory effects in women (7) (8) (9) (10) (11) (12) . Because the antifertility effects of LH-RH and its analogs are parallel to their gonadotropin-releasing potency, the loss of ovarian gonadotropin receptors and inhibition of steroidogenesis could be due at least partly to endogenous luteinizing hormone (LH) release (5, 11, 13) . However, direct ovarian effects of LH-RH agonists have been observed in female rats (14) (15) (16) (17) . LH-RH agonists have also been found to inhibit steroid secretion stimulated by human choriogonadotropin or follicle-stimulating hormone in rat luteal and granulosa cells (17) (18) (19) . These data suggest that LH-RH agonists have a direct ovarian site of inhibitory action that could play a role in their antifertility effect. This concept has been further strengthened by the recent demonstration of specific uptake of a labeled LH-RH agonist in the rat ovary (15) (approximately 150,000 cpm, 0.5 nM), 100,ul of unlabeled peptide at the appropriate concentration, and 100 y1 of anterior pituitary or ovarian homogenate. The incubation was performed at 0-4CC for 120 min and the reaction was stopped by the addition of 3 ml of ice-cold pH 7.6 buffer. Tubes were then centrifuged at 2000 X g for 25 min and the radioactivity contained in the pellet was assayed in a gamma counter with 60% efficiency. Measurement of Biological Activity and Calculations. The agonistic and antagonistic activities of the LH-RH analogs were measured as the potency of the peptides to stimulate and inhibit, respectively, the LH-RH-induced LH release in rat anterior pituitary cells in primary culture (23) (24) (25) . Kd values for LHreleasing activity were determined as the peptide ED5o for LH release. These results-were analyzed with an iterative nonlinear least squares regression (26) . For antagonistic activity, compounds were tested for their ability to inhibit LH release in the presence of 0.3 or 3 nM LH-RH. Kd values were calculated according to the equation Kd = ED o/(1 + S/K), in which S is the concentration of LH-RH, K is the Kd value of LH-RH action of LH release (0.3 nM), and EDso is the concentration of the LH-RH antagonist giving 50% reversal of LH-releasing ability (27) . (Fig. 2A) (Table 1) suggests that the affinity of the various peptides can account, at least up to a large extent, for the increase in biological activity; their ability to resist enzyme degradation may be of lesser importance, as previously suggested (32) . A D amino acid in position 6 stabilizes the LH-RH molecule and provides a conformation having greater affinity for the receptor (35) .
These findings are supported by the demonstration of prolonged retention of LH-RH agonists in vivo in the pituitary, up to 6 hr after administration (33) , whereas plasma disappearance rates of iodinated LH-RH and an agonistic LH-RH analog have been shown to be identical in vio in the sheep (36) . However, the lack of perfect correlation between binding to the LH-RH receptor and LH release suggests that factors other than binding affinity are involved in the activity of these peptides. Because the binding assay was performed at 0-40C, whereas LH release was measured at 370C, it is possible that the differences observed are related to the influence of temperature on the conformation of the receptor or the LH-releasing peptides.
The finding of similar apparent dissociation constants when the characteristics of (125I)[D-Ser(TBU)6]-LH-RH-EA binding were analyzed from dose-response curves obtained with both the labeled and the unlabeled peptide demonstrates that 125I does not alter the affinity of the molecule.
When the affinities of the antagonists are evaluated, it can be seen that removal of His2 decreases binding in both the pituitary and ovary (Fig. 3) Although the order of potency of the various antagonists is similar in both the receptor assay and the bioassay, these peptides showed a 10-to 30-fold higher affinity in the former. This finding is analogous to the binding specificity of the dopaminergic agonist [3H]dihydroergocryptine in bovine anterior pituitary membranes (37) (38) .
The present demonstration of LH-RH receptors having almost superimposable binding characteristics in the anterior pituitary and ovary indicates that the antifertility effects of LH-RH and its agonists could be mediated partly by their action through ovarian LH-RH receptors. The concentration of LH-RH in the portal blood system of the rat has been reported as 150 pg/ml (39) . This observation, combined with the fact that LH-RH is diluted 1:500 between the portal circulation and the jugular vein (40) , makes it unlikely that hypothalamic LH-RH could have a physiological action on ovarian LH-RH receptors. However, it would also be somewhat unexpected to have specific ovarian LH-RH receptors that are not linked to a physiological function. Although the possibility of an action of hy-pothalamic LH-RH at the ovarian level must be further investigated, the presence of specific ovarian LH-RH receptors raises the possibility that LH-RH secreted locally could be involved in the control of ovarian activity, a new area of investigation which should be of great biological interest.
